Nucresiran
Asset
Silences hepatic TTR messenger RNA, reducing transthyretin production and amyloid formation.
- Stage
- Phase 3
- Modality
- Oligonucleotide
- Target
- Proteostasis
- 2
- Indications
- 1
- Trial
- 1
- Developer
Indications
2HATTR-PN
Phase 3, Recruiting, NCT07223203, clinicaltrials.gov, 11 Oct 2026
Hereditary transthyretin-mediated amyloidosis with polyneuropathy
Phase 3, Recruiting, NCT07223203, clinicaltrials.gov, 11 Oct 2026
In the full profile
- Targets and what it contains2
- Owner and partners1
- Trials1
- Evidence for its targets2
- Competitors6
- Aging relevance1
- Signals2
Every asset’s record: target, stage, trials and the evidence behind it.